One study showed that MET-dependent NSCLC cells that had become resistant displayed high levels of c-Met and KRAS (kirsten rat sarcoma viral oncogene homolog) amplification, leading to downstream MAP kinase activity [6]. The gene discussed is MET; the disease is non-small cell lung carcinoma.